Crohn's & Colitis Foundation

Could preventing inflammatory bowel disease (IBD) become a reality? In our new Inflammatory Bowel Diseases® Journal special supplement, researchers explore the role of genetics, early-life environmental risks, and promising new biomarkers that are paving the way for helping us understand how to predict and alter the course of Crohn’s disease and ulcerative colitis. The ultimate goal? Shift the focus from treating IBD to truly preventing it, transforming the future for millions. https://bit.ly/4nWVMbg

The most innovative minds in IBD science, technology, and clinical care will be at the 2026 Crohn’s & Colitis Congress® in Las Vegas, Jan. 22–24. This year's cutting-edge content includes hot topics, interactive sessions, expert panels, valuable CME/MOC programs, and so much more! Check out the full #CCCongress26 agenda to customize your learning experience. Advanced discounts expire on Tuesday, October 21—hurry and register now to be part of the future of #IBD care. Visit 🔗 https://bit.ly/46tEJI2 American Gastroenterological Association (AGA)

Get the latest jobs and industry news

IBD research is moving toward treatments that could do more than control inflammation—they may help change the long-term course of Crohn’s disease and ulcerative colitis. Realizing that potential requires looking beyond a single snapshot of disease. By combining multiple types of biological data with long-term clinical information and patient outcomes, researchers can better understand disease pathways, identify patients who may benefit from new treatments, and evaluate whether treatment benefits last over time. Learn how the Foundation's research ecosystem, IBD Plexus, is helping advance the next generation of IBD therapies in a new article by Angela Dobes, the Foundation's Senior Vice President of IBD Plexus.

IBD drug development is expanding beyond single-target immunosuppression toward mechanisms capable of altering the long-term disease course. Proving their potential requires looking beyond cross-sectional data. Integrating high-dimensional multi-omics with longitudinal clinical and patient outcomes enables teams to validate active disease pathways, enrich trial cohorts, and demonstrate durability before entering the clinic. Read how our IBD Plexus Causal-Context framework applies multimodal data to de-risk the next generation of IBD therapeutics.